---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268319"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:02:16.746072+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Phathom's VOQUEZNA for Erosive GERD; triggers $175M payment

## Summary
- FDA approved VOQUEZNA (vonoprazan) for healing, maintenance, and heartburn relief in Erosive GERD.
- Phase 3 PHALCON-EE trial showed 93% healing rate at Week 8 for VOQUEZNA 20mg vs 85% for lansoprazole.
- VOQUEZNA demonstrated superiority in moderate-to-severe patients (70% vs 53% at Week 2).
- Approval triggers a $175M non-dilutive payment from Revenue Interest Financing Agreement.
- VOQUEZNA expected to launch in US in December 2023; marketed exclusively by Phathom.

## SEC filing metadata
- accession: 0001193125-23-268319
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523268319/0001193125-23-268319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523268319/d579199d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268319
- JSON: https://secwatch.observer/filing/0001193125-23-268319.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.